The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to naproxcinod, an investigational…
Margarida Azevedo, MSc
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Azevedo, MSc
Dilated Cardiomyopathy Using Induced Pluripotent Stem Cells Derived From Duchenne Muscular Dystrophy
A recent study published in the journal Disease Models & Mechanisms uncovered important underlying molecular mechanisms associated…
Findings from a recent case report published online in the journal Respiratory Medicine Case Reports suggest that patients with …
Israeli biotech company BioBlast Pharma Ltd. has received clearance from the U.S. Food and Drug…
The Muscular Dystrophy Association’s president and CEO opened its 2015 Scientific Conference in Washington this week by underscoring the…
Real estate franchiser ERA is launching the ERA MDA Summer Camp Challenge, a campaign in collaboration with the Muscular…
Biopharmaceutical company PTC Therapeutics, Inc. is not only developing a protein restoration therapy for the treatment of nonsense mutation…
The Muscular Dystrophy Association (MDA) is gathering the support of local communities throughout the country for another…
Over 150 advocates associated with the organization Parent Project Muscular Dystrophy (PPMD) gathered on Capitol Hill for PPMD’s Annual Advocacy…
One of the largest networks of fertility experts in California, Advanced Reproductive Care (ARC) Fertility, is advocating for the performance of new preimplantation…